Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.07
-0.0500-0.82%
Post-market: 6.140.0700+1.15%19:09 EDT
Volume:1.43M
Turnover:8.72M
Market Cap:723.21M
PE:-13.65
High:6.24
Open:6.12
Low:5.98
Close:6.12
Loading ...

Trevi Therapeutics Inc. Held Annual Stockholders Meeting

Reuters
·
Yesterday

Trevi Therapeutics Closes $115 Million Public Offering, Underwriters Fully Exercise Option for Additional Shares

Reuters
·
06 Jun

BRIEF-Trevi Therapeutics Inc - Expects Cash Resources To Fund Operations Into 2029

Reuters
·
05 Jun

Trevi Therapeutics Inc - Expects Cash Resources to Fund Operations Into 2029 - SEC Filing

THOMSON REUTERS
·
05 Jun

BUZZ-U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy,  MongoDB

Reuters
·
05 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Trevi Therapeutics, Cactus, Copper miners

Reuters
·
04 Jun

Trevi Therapeutics Inc. Announces $100 Million Public Offering of Common Stock

Reuters
·
04 Jun

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
04 Jun

Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $23 From $20

THOMSON REUTERS
·
03 Jun

BUZZ-Trevi Therapeutics slips on $100 mln stock sale plans

Reuters
·
03 Jun

Shares of Trevi Therapeutics Down 2.6% in Extended Trade; Co Launches $100 Mln Public Stock Offering

THOMSON REUTERS
·
03 Jun

Trevi Therapeutics Launches $100 Million Public Stock Offering to Fund Clinical Developments

Reuters
·
03 Jun

Trevi Therapeutics Inc - Announces $100 Mln Public Offering of Common Stock

THOMSON REUTERS
·
03 Jun

Trevi Therapeutics Inc - Expects to Grant Underwriters 30-Day Option for Additional $15 Mln

THOMSON REUTERS
·
03 Jun

Trevi Therapeutics Announces Positive Results from Phase 2b CORAL Trial of Haduvio for Chronic Cough in IPF Patients, Plans Phase 3 Initiation in 2026

Reuters
·
02 Jun

Trevi Therapeutics Announces Positive Topline Results From the Phase 2B Coral Trial of Haduvio in Patients With Idiopathic Pulmonary Fibrosis Chronic Cough

THOMSON REUTERS
·
02 Jun

Trevi Therapeutics Inc - to Request End-of-Phase 2 Meeting With FDA, Phase 3 in 2026

THOMSON REUTERS
·
02 Jun

Trevi Therapeutics Inc - Haduvio Met Primary Endpoint , Achieves -43.3% Placebo-Adj Change in Cough Frequency at 108 Mg Bid

THOMSON REUTERS
·
02 Jun

Trevi Therapeutics Inc - Haduvio Well-Tolerated With Similar Discontinuation Rates to Placebo

THOMSON REUTERS
·
02 Jun

Trevi Therapeutics to Present at American Cough Conference in Dulles, Virginia

Reuters
·
29 May